Bicycle Therapeutics expands Genentech immuno-oncology collaboration; receives $10M option exercise payment

BICYCLE THERAPEUTICS PLC

Genentech exercised second option to add a new program to the existing 2020 collaboration, triggering a $10M payment to Bicycle.
First expansion option under the same agreement was exercised in October 2021, also for $10M.
Collaboration covers discovery and preclinical development of novel Bicycle-based immunotherapies against multiple targets.
Bicycle's wholly owned oncology pipeline, including its immuno-oncology candidates, is not part of the collaboration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.